Ancell mAbs were used by this Cal State Research group to block trogocytic killing of Triconomas Vaginelas parasite by human PLB-95 Neutrophil-Like-cells in vitro. Blocking CD11c and CD18 receptors on NLC with antibodies resulted in significant reduction of killing, implicting CR3 mediated complement fixation as the primary mechanism. “Complement receptor 3 is required for maximum […]

Russian Researchers investigating Redox processes in Neutrophil activation. “Redox processes are major regulators of leukotriene synthesis in neutrophils exposed to bacteria Salmonella typhimurium; the way to manipulate neutrophil swarming” E A Golenkina, G F Sud’ina, et al. (Feb 2024) Front. Immunol 15 (06 February 2024) PMID: 38384456 PMCID: PMC10880102 DOI: 10.3389/fimmu.2024.1295150 . Relevant Ancell Products

Researchers investigating the role of Siglec-5 in Neutrophil activation. “SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity” P Bouti, HL Matlung et al. (Dec 2023) Int J Mol Sci 24(24): 17141. https://doi.org/10.3390/ijms242417141 Relevant Ancell Products anti-human CD18 products anti-human CD11b products anti-human CD47 products Recombinant human CD54-muIg

Acute Coronary Syndrome(ACS) was simulated by provoking healthy PBMC with autoimmune self antigen pepetide LL-37. Effect of blockade on HLA Class I, Class II, PD-1 and CTLA-4 on T cell expression of Activation Induced Molecules (AIM) was then examined. “Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome” Chernomordik F, PC Dermayuga, et al.

“Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences” Marelia Barreca, et al. Explor Target Antitumor Ther. 2022; 3(6): 763–794. Published online 2022 Dec 26. doi: 10.37349/etat.2022.00112 PMID: 36654819 Relevant Ancell Research Products anti-human CD269(BCMA) mAb human CD269(BCMA) Recombinant Protein anti-human CD22 mAb anti-human CD79b anti-CD19 mAb

“Prenol, but Not Vitamin C, of Fruit Binds to SARS-CoV-2 Spike S1 to Inhibit Viral Entry: Implications for COVID-19” Ramesh K. Paidi , Kalipada Pahan , et al. (May 2023) Journal of Immunology 210 (12): 1938–1949. https://doi.org/10.4049/jimmunol.2200279 PMID: 37144841

Using a yeast display system, his group developed a BCMA mutant with higher affinity to TNF ligands APRIL and BAFF. This soluble decoy receptor showed anti-tumor effects in vitro and in vivo using mouse MM1.R and INA-6 tumor models. “Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma” Yu Rebecca

Plasma derived neuronal enriched extracellular vesicles(EVs) were evaluated for content of α-synuclein and phosphorylated tau181. Ratio of α-synuclein to phosphorylated tau181 in these samples was signicantly higher for cognitively impaired Parkinson’s patients compared to cognitively normal Parkinson’s patients. Analysis of plasma EVs may be useful for prognosis of Parkinson’s disease. “Extracellular vesicle biomarkers for cognitive

“Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies” doi: 10.1136/jitc-2022-005018. PMID: 36323431 Karin Hägerbrand , Peter Ellmark, et al. J Immunother Cancer 2022 Nov;10(11):e005018 Tetrameric Bispecific antibodies specific to CD40 and either CD326(EpCAM) or CD66e(CEA) were tested on human cells in vitro

This study looked at the effect of glycosylation of anti-platelet antibody on ability of Macrophage mediated phagocytotic clearance in transfusion patients. F(ab’)2 of anti-CD64 mAb was used as a phagocytosis blocking control in vitro. “Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages“ Thijs L, Gesture Vidarsson, et al. Platelets  (2022) https://doi.org/10.1080/09537104.2022.2129604